Original ArticlePhase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study
Under an Elsevier user license
open archive
Key Words
Elderly
Exisulind
Sulindac sulfone
Non-small cell lung cancer
Vinorelbine
Phase I
Phase II
Cited by (0)
Supported by P30 CA14520 (KMK) and National Institutes of Health grant T32 CA009614 Physician Scientist Training in Cancer Medicine (SA), and OSI Pharmaceuticals (Melville, NY).
Disclosure: KMK serves as consultant to OSI on an unrelated project, not involving exisulind.
Copyright © 2008 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.